March 9 and 10 at Paris Expo – Porte de Versailles, Hall 5
SATT Nord will focus in particular on projects:
Across:Treatment of chronic inflammatory bowel diseases.
Medelopt : Range of medical devices enabling the combined analysis of electrical activity (using electroencephalography) and tissue oxygen consumption (using near-infrared spectroscopy).
Gal 9 : Specific antibodies that help to re-energize the immune system in certain diseases such as cancer.
LSR : Molecule targeting an intracellular receptor involved in neurodegenerative diseases such as multiple sclerosis
Pyflup : Molecules for the treatment of respiratory diseases
Pulmolast : New elastin receptor antagonist peptides for the treatment of lung diseases
Pyroseq : Detection of antibiotic resistance using a molecular sequencing method
Qafsi: Automated detection, characterization, and quantification tool using Fourier transform infrared spectroscopy
Techflax : Cosmetic active ingredient derived from flaxseed mucilage, indicated for use in face and body care products to prevent and combat skin aging
Cygal : New pharmaceutical excipient improving the bioavailability of active ingredients
ProNGF: Combination therapy combining two molecules aimed at overcoming resistance mechanisms in breast cancers resistant to first-line chemotherapy.
Find all of our healthcare projects: https://sattnord.fr/entreprises/offre-de-technologies/offre-techno-5/
You can contact our healthcare business developers and schedule an appointment with them during these two days of the conference:
François-Xavier Denimal: Tel: +33.6.13.84.36.28 – francois-xavier.denimal@sattnord.fr
Hervé Ansanay: Tel: +33.6. 13.84.39.39 – herve.ansanay@sattnord.fr
More information about the Bio Europe Spring 2015 conference:http://www.ebdgroup.com/bes/travel/index.php